Skip to content

ELOXX PHARMACEUTICALS, INC.: 10-Q filed 2014-02-14

What ELOXX PHARMACEUTICALS, INC. reported in its quarterly report filed 2014-02-14 (fiscal Q2 2014): 26 published measures, 83 facts as tagged in accession 0001144204-14-009665.

This filing

Form
10-Q (quarterly report)
Filed
2014-02-14
Fiscal period
fiscal Q2 2014
Accession
0001144204-14-009665 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ELOXX PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-12-3111,101,431USD
At 2013-06-307,097,737USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2013-12-313,381,341USD
At 2013-06-303,311,670USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-12-317,720,090USD
At 2013-06-303,786,067USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2013-12-316,121,895USD
At 2013-06-301,602,294USD
At 2012-12-31640,125USD
At 2012-06-302,001,325USD
At 1998-06-300USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-10-01 to 2013-12-31-1,619,638USD92
2013-07-01 to 2013-12-31-3,403,971USD184
1998-07-01 to 2013-12-31-66,463,267USD5663
2012-10-01 to 2012-12-31-1,269,885USD92
2012-07-01 to 2012-12-31-3,355,339USD184

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-07-01 to 2013-12-31-2,092,404USD184
1998-07-01 to 2013-12-31-43,017,420USD5663
2012-07-01 to 2012-12-31-1,201,869USD184

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2013-07-01 to 2013-12-310USD184
1998-07-01 to 2013-12-31185,947USD5663
2012-07-01 to 2012-12-311,281USD184

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-07-01 to 2013-12-316,865,237USD184
1998-07-01 to 2013-12-3156,330,967USD5663
2012-07-01 to 2012-12-3194,183USD184

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2013-07-01 to 2013-12-31-253,232USD184
1998-07-01 to 2013-12-31-7,191,652USD5663
2012-07-01 to 2012-12-31-253,514USD184

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2013-12-313,512USD
At 2013-06-304,555USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2013-10-01 to 2013-12-31342,791USD92
2013-07-01 to 2013-12-31467,257USD184
1998-07-01 to 2013-12-3113,297,903USD5663
2012-10-01 to 2012-12-31196,567USD92
2012-07-01 to 2012-12-31350,129USD184

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2013-10-01 to 2013-12-31-1,588,907USD92
2013-07-01 to 2013-12-31-3,341,636USD184
1998-07-01 to 2013-12-31-60,961,642USD5663
2012-10-01 to 2012-12-31-1,300,047USD92
2012-07-01 to 2012-12-31-2,546,200USD184

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-12-317,610,360USD
At 2013-06-303,521,514USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-12-313,281,613USD
At 2013-06-303,211,942USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2013-12-31477,628USD
At 2013-06-30637,320USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2013-10-01 to 2013-12-31647,123USD92
2013-07-01 to 2013-12-311,374,242USD184
1998-07-01 to 2013-12-3124,696,513USD5663
2012-10-01 to 2012-12-31591,079USD92
2012-07-01 to 2012-12-311,104,512USD184

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2013-12-314,957,275shares
At 2013-06-302,272,062shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2013-12-3185,542,557USD
At 2013-06-3078,189,173USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2013-12-313,482,388USD
At 2013-06-303,566,497USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2013-12-3199,728USD
At 2013-06-3099,728USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2013-12-31616,903USD
At 2013-06-30387,540USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2013-10-01 to 2013-12-31-1,640,255USD92
2013-07-01 to 2013-12-31-3,446,211USD184
1998-07-01 to 2013-12-31-77,872,046USD5663
2012-10-01 to 2012-12-31-1,293,871USD92
2012-07-01 to 2012-12-31-4,003,494USD184

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2013-10-01 to 2013-12-31-1,640,255USD92
2013-07-01 to 2013-12-31-3,446,211USD184
1998-07-01 to 2013-12-31-77,872,046USD5663
2012-10-01 to 2012-12-31-1,293,871USD92
2012-07-01 to 2012-12-31-4,003,494USD184

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2013-10-01 to 2013-12-31941,784USD92
2013-07-01 to 2013-12-311,882,233USD184
1998-07-01 to 2013-12-3135,996,534USD5663
2012-10-01 to 2012-12-31708,968USD92
2012-07-01 to 2012-12-311,441,688USD184

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2013-10-01 to 2013-12-3177,910USD92
2013-07-01 to 2013-12-31152,180USD184
2012-10-01 to 2012-12-3166,203USD92
2012-07-01 to 2012-12-31129,128USD184

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2013-07-01 to 2013-12-31-159,692USD184
1998-07-01 to 2013-12-31477,628USD5663
2012-07-01 to 2012-12-31491,115USD184

Inspect the source

Entity
ELOXX PHARMACEUTICALS, INC. / CIK 0001035354
Captured
2026-09-20T05:15:09.498Z
SEC response SHA-256
b351a9ed06ee3e6f1d738bbdb3852b866526fe561e11a7ffd4a81bc43bb27195

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001035354.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))